# A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

> **NCT07421232** · PHASE2 · COMPLETED · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 156 (actual)

## Conditions studied

- Hypercholesterolemia and Mixed Hyperlipidemia

## Interventions

- **DRUG:** SYH2053/placebo injection
- **DRUG:** Inclisiran (Leqvio®) 300mg

## Key facts

- **NCT ID:** NCT07421232
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-03
- **Primary completion:** 2025-08-30
- **Final completion:** 2026-02-12
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07421232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07421232, "A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07421232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*